Category: Press Release

ITHACA, NY, USA, March 1, 2010 — Advion BioSystems, Inc. (Advion) announces the launch of its Liquid Extraction Surface Analysis (LESA) sample analysis system. LESA, based on Advion’s chip-based nanoelectrospray platform, the TriVersa NanoMate®, will be used to provide direct Mass Spectrometric analysis of a variety of sample formats including tissue and organ samples, Thin Layer Chromatography (TLC) plates, MALDI plates, and Dried Blood Spots (DBS).

The direct analysis of surfaces by mass spectrometry is a growing and powerful technique. The novel approach and design of the Advion LESA system enables, for the first time, the ability to couple direct analysis of surfaces with the power and breadth of chip-based nanoelectrospray. This simple-to-use combination allows for soft ionization, thereby preserving fragile molecules such as phase 2 metabolites and allowing unrivalled detection of drugs and their metabolites in tissue and organ samples. Researchers developing new forensic tools, novel drugs, better biofuels and technologies to strengthen homeland security now have a powerful new tool to use to analyze a variety of surfaces.

The new system was developed by Oak Ridge National Laboratory (ORNL), a multiprogram science and technology laboratory managed for the U.S. Department of Energy by UT-Battelle, which exclusively licensed the technology to AB SCIEX, a global leader in life science analytical technologies. In parallel, Advion signed an exclusive sublicense agreement with DH Technologies Development Pte. Ltd., an AB SCIEX affiliate, to commercialize certain discoveries and pending patents that leverage the Advion TriVersa NanoMate product lines used in the ORNL research in conjunction with AB SCIEX mass spectrometers.

“The launch of this innovative sample analysis system is extremely strategic for our company,” said David B. Patteson, CEO of Advion. “This is the result of our working closely with ORNL and AB SCIEX dating back nearly seven years to early discussions between Jack Henion – our Chairman and CSO – and our partners. We expect significant impact from our customers applying this technique to a myriad of sample types and conditions, which to date have been difficult to assay.”

About Advion BioSystems, Inc.
Advion is the scientific leader in microfluidic systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the microfluidics supplier of choice for customers demanding scientific excellence, more information from complex samples, and greater throughput. More about the company can be found at www.advion.com.

For Advion:
Heather Scollins
Sr. Marketing Communication Specialist
Advion BioSciences, Inc.
p: 1.607.266.0665 ext. 333
hscollins@advion.com

ITHACA, NY, USA, February 5, 2010 — Advion BioSystems, Inc. (Advion) announced the issuance of U.S. patent No. 7641860 for their reconfigurable multistage microreactor cartridge apparatus, a key module of the Advion NanoTek Microfluidic Synthesis System (NanoTek), which is primarily used by leading Positron Emission Tomography (PET) radiochemists around the world.

PET, which uses specific biomarkers labeled with small amounts of radioactivity, is a powerful technique used in both clinical diagnostic medicine and in advanced medical research and pharmaceutical development. The core technology of the NanoTek system, microfluidic flow chemistry, has proven to be an attractive alternative to conventional vial-based chemistry for radiochemical labeling. The advantages include reduced reaction times and higher radiochemical yields. Researchers who have utilized the NanoTek system in their labs report the ability to conduct multiple sequential syntheses from one delivery of radioisotope, greatly accelerating the optimization of new compounds.

Andy Holley, NanoTek Product Manager, states, “This component enables our users to rapidly reconfigure the NanoTek system for different syntheses. We are pleased that this innovative technology has been recognized and is now protected by the granting of this patent.”

Jack Henion, Co-founder and Chief Scientific Officer of Advion added, “Advion is proud of our track record in innovative research. The granting of this patent is yet one more confirmation of our leadership in microfluidic technology.”

About Advion BioSystems, Inc.
Advion is the scientific leader in microfluidic systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the microfluidics supplier of choice for customers demanding scientific excellence, more information from complex samples, and greater throughput. More about the company can be found at www.advion.com.

For Advion:
Heather Scollins
Sr. Marketing Communication Specialist
Advion BioSciences, Inc.
p: 1.607.266.0665 ext. 333
hscollins@advion.com

September 9, 2009 – Ithaca , NY – Advion BioServices, Inc., a leading contract research organization serving pharmaceutical and biotechnology partners worldwide, today announced the expansion of its existing LC/MS Biomarker Services Group. The expansion comes in response to increased interest from leading pharmaceutical companies in the use of biomarkers as cost-effective indicators of pharmacological response to drugs. The company will assign an increased commitment of staffing, Thermo Scientific and Applied Biosystems mass spectrometers, liquid chromatography and automated liquid handling systems to this service.

At the forefront of the contract research industry, Advion originally launched its LC/MS Biomarker Services Group in 2008 to complement its ligand-binding services. Since then, the group has developed and delivered to its clients unique, fit-for-purpose assays for peptide, amino acid, lipid, neurotransmitter, and nucleotide biomarkers. These methods, from exploratory to definitive quantitation assays, are customized to client requirements and have proven a popular approach for supporting a wide range of biomarker programs.

“Expansion of our LC/MS Biomarker Services Group reflects an increasing demand for biomarker methods as companion assays to other bioanalytical approaches needed for the development of new drugs,” says Dr. Stephen Lowes , Advion BioServices’ Senior Vice President, Science. “The FDA has acknowledged that biomarkers can help pharmaceutical companies streamline expensive, later-phase clinical trials by using fewer subjects or patients. Our extensive experience with mass spectrometry, immunoassays, and sample management means that we can meet the need for rapid biomarker assay development, validation, and sample analysis. The customer demand for LC/MS biomarker assays has made this an exciting time for the company.”

Under the direction of Dr. Lowes, the group is led by Dr. Gary Schultz , Senior Director, Biomarkers, who has played a key role at Advion in developing innovative tools and methods for biomarker analysis including the ESI Chip® , TriVersa NanoMate® , and RePlay® proteomics system.

About Advion BioServices, Inc.
Advion is a scientific leader in bioanalytical and immunoassay services. Advion offers a range of GLP-compliant and discovery support services including bioanalytical LC/MS/MS, LC/MS biomarker analysis, immunoassay, dose formulation analysis, P450 inhibition study support, sample management, and sample storage. The company is the laboratory of choice for pharmaceutical and biotechnology companies in pursuit of scientific excellence.

For more information on the Biomarker Services Group, please call 1-607-266-0665, email info@advion.com or visit http://www.quintiles.com/clinical-services/bioanalytical-laboratories/biomarker-services/. More information about the company can be found on its website www.advion.com.

For Advion:
Heather Scollins
Senior Marketing Communication Specialist
Advion BioSciences, Inc.
P: 1.607.266.0665 ext. 333
hscollins@advion.com

BREMEN, Germany, August 31, 2009 — Advion BioSystems, Inc. (Advion) and Waters Corporation (NYSE:WAT) jointly announced today at the 18th International Mass Spectrometry Conference (IMSC) that Advion’s TriVersa NanoMate® chip-based nanoelectrospray ionization system is now compatible with the full range of Waters® mass spectrometry (MS) systems including the newest Xevo™ and SYNAPT™ G2 systems. The TriVersa NanoMate is an automated fraction collection and nanoelectrospray system that connects to the inlet of a mass spectrometer. It combines the benefits of micro or capillary-scale liquid chromatography (LC), with simultaneous fraction collection and subsequent chip-based infusion of the LC fractions in one system to increase the performance and automation of MS, allowing analysts to obtain more information from complex samples than with LC/MS alone.

Advion and Waters have collaborated to interface the TriVersa NanoMate to the latest high performance MS systems from Waters. These include Waters SYNAPT G2 MS, SYNAPT G2 High Definition Mass Spectrometry™ (HDMS™) platform, Xevo TQ MS, and Xevo QTof, a quadrupole time-of-flight (QTof) mass spectrometer.

“We are really excited about the combination of the TriVersa NanoMate with the latest Xevo and SYNAPT G2 instruments,” said Jack Henion, Advion’s Chief Scientific Officer. “The unique ability of the TriVersa to perform online LC/MS while collecting fractions for later infusion, coupled to the high resolution, exact mass TOF-MS systems from Waters provides a compelling, versatile tool for antibody analysis, proteomics, metabolite identification and profiling, metabolomics, natural products and many other chemical and biochemical analyses.”

Advion has also launched DualSpray™ which provides LockSpray™ capability when using the TriVersa NanoMate with the Waters QTof Premier™, QTof Micro™, SYNAPT MS and SYNAPT HDMS instruments. DualSpray provides a second nanoelectrospray to provide a reference ‘lock’ mass in the same way that Waters’ own LockSpray system does, under full control of the Waters MassLynx™ software.

Advion will begin shipments of DualSpray technology for the new Waters Xevo and SYNAPT G2 mass spectrometer product lines in December 2009.

For More Information

For additional product information on Advion’s TriVersa NanoMate and DualSpray technology, please visit www.advion.com/TVNM.

For more product information on Waters SYNAPT G2 mass spectrometers and Waters family of Xevo mass spectrometers, go to www.waters.com/synaptG2 and www.waters.com/xevo, respectively.

About Advion BioSystems, Inc.
Advion is the scientific leader in microfluidic systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the microfluidics supplier of choice for customers demanding scientific excellence, more information from complex samples, and greater throughput. More about the company and how its technology is enhancing the power of mass spectrometry can be found at www.advion.com.

About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT) creates business advantage for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety and water quality worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.58 billion in 2008 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.

# # #

Waters, Synapt, Xevo, QTof, High Definition MS, HDMS, MassLynx, QTof Premier, and QTof micro are trademarks of Waters Corporation.

Advion, Advion BioSystems, TriVersa NanoMate and DualSpray are trademarks of Advion BioSciences, Inc.

For Advion:
Heather Scollins
Sr. Marketing Communication Specialist
Advion BioSciences, Inc.
p: 1.607.266.0665 ext. 333
hscollins@advion.com

ITHACA, NY, USA and Louvain-LA-Neuve, Belgium, June 13, 2009 — Advion BioSystems, Inc. and Ion Beam Applications (IBA) jointly announced today a new agreement for IBA to be a world-wide non-exclusive agent for the Advion NanoTek Microfluidic Synthesis System (NanoTek). Under the agreement, IBA will focus their efforts on offering the NanoTek as an optional accessory when proposing solutions for turnkey cyclotron projects involved with Positron Emission Tomography (PET). IBA will also offer it to existing installed base cyclotrons.

Said Peter Leitner, Sales & Marketing Director of IBA, “Our cyclotrons are used in many leading PET research centres around the world, and we are pleased to be able to offer our customers access to this exciting new technology from Advion.”

Dave Patteson, CEO of Advion, added, “This agreement will widen our distribution channels, enabling us to participate in the world wide market for turnkey PET radiochemistry departments.”

PET, which uses specific biomarkers labeled with small amounts of radioactivity, is a powerful technique used in both clinical diagnostic medicine and in advanced medical research and pharmaceutical development. The core technology of the NanoTek, microfluidic flow chemistry, is rapidly proving to be an attractive alternative to conventional vial-based chemistry for the radiochemical labeling. The advantages include reduced reaction times and higher radiochemical yields. Researchers, who have already incorporated the NanoTek into their labs, report being able to conduct multiple sequential syntheses from one delivery of radioisotope, greatly accelerating the optimization of new compounds.

About IBA
Founded in 1986 in Louvain-la-Neuve , Belgium , IBA is primarily active in the medical industry. It develops and markets state-of-the-art equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus gained to provide electron accelerators for industrial sterilization and ionization.

About Advion BioSystems, Inc.
Advion is the scientific leader in microfluidic systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the microfluidics supplier of choice for customers demanding scientific excellence, more information from complex samples, and greater throughput. More about the company can be found at www.advion.com.

For Advion:
Heather Scollins
Sr. Marketing Communication Specialist
Advion BioSciences, Inc.
p: 1.607.266.0665 ext. 333
hscollins@advion.com

ITHACA, NY, and SANTA CLARA, Calif., November 12, 2008 — Advion BioSystems, Inc. and Agilent Technologies Inc. (NYSE: A) jointly announced today that they have signed a non-exclusive co-marketing agreement to co-promote the Advion TriVersa NanoMate system with Agilent mass spectrometers. The TriVersa NanoMate is an automated fraction collection and nanoelectrospray system that connects to the inlet of a mass spectrometer. It combines the benefits of micro or capillary-scale liquid chromatography (LC), with simultaneous fraction collection and subsequent chip-based infusion of the LC fractions in one system to increase the performance and automation of a mass spectrometer.

The TriVersa NanoMate differs from Agilent’s 1200 Series HPLC-Chips in that the former operates at capillary and micro flow rates needed for fraction collection, enabling collection of individual peaks for highly sensitive infusion MS analysis. The latter provides on-line LC/MS at nanoflow rates that are well-suited to applications where the amount of sample available is limited.

Agilent and Advion have co-developed a bracket to interface the TriVersa NanoMate to Agilent mass spectrometers to provide life science users with the power of automated sample infusion on the Agilent family of LC/MS systems.

Under the agreement, the companies will co-market the TriVersa NanoMate and Agilent mass spectrometer systems with each company responsible for its individual products. Agilent will sell and support its mass spectrometers and Advion will sell and support the TriVersa NanoMate and the bracket to interface the TriVersa NanoMate to Agilent mass spectrometers. Each company will co-promote their products at industry tradeshows and conferences.

“The combination of the TriVersa NanoMate with Agilent mass spectrometers provides a powerful tool for life science researchers,” said Jack Henion , Advion’s Chief Scientific Officer. “In particular, the efficiency and sensitivity of direct infusion of LC fractions with the TriVersa NanoMate and the new Agilent 6530 Accurate-Mass Q-TOF instrument provides researchers with exceptional sensitivity and speed for proteomics, metabolism, lipidomics, and biomarker applications.”

Ken Miller, Global Sr. Marketing Manager for Mass Spectrometry at Agilent, added, “ The Advion TriVersa Chip-based system will be very complementary to the Agilent nanoflow HPLC-Chip technology. The TriVersa system offers some added capabilities such as fraction collection of peaks of interest and should prove to be very useful for protein characterization and biomarker discovery experiments. Many of our customers have asked for the integration of the Advion system with our 6000 Series LC/MS products, especially the Agilent 6500 Accurate Mass Q-TOF LC/MS system.”

Agilent manufactures and markets life science and chemical analysis solutions and is a worldwide leader in mass spectrometry, with powerful, reliable LC/MS solutions for applications as diverse as discovery of cancer biomarkers and quantification of pesticides in food and water. Advion provides innovative microfluidic systems for mass spectrometry (MS) and nuclear medicine applications.

About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 20,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.4 billion in fiscal year 2007. Information about Agilent is available on the Web at www.agilent.com.

About Advion BioSystems, Inc.
Advion is the scientific leader in microfluidic systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the microfluidics supplier of choice for customers demanding scientific excellence, more information from complex samples, and greater throughput. More about the company can be found at www.advion.com.

For Advion:
Heather Scollins
Sr. Marketing Communication Specialist
Advion BioSciences, Inc.
p: 1.607.266.0665 ext. 333
hscollins@advion.com

July 1, 2008 – Ithaca , NY – Advion BioServices, Inc., a specialty contract research organization, today announced that it has expanded its bioanalytical service capabilities by adding five new triple quadrupole mass spectrometers to its laboratory in Ithaca, New York. Included in this investment are the industry-leading API 5000™ LC/MS/MS System and API 4000™ LC/MS/MS System from Applied Biosystems/MDS Analytical Technologies, a leader in mass spectrometry.

With this purchase, Advion brings its total of new mass spectrometers acquired in the past year to seven. These additional instruments provide Advion with increased LC/MS capacity to meet growing client demands and the ability to provide its clients with an expanding array of bioanalytical services.

According to Jack Henion, PhD, Chief Scientific Officer, Advion, “Utilizing state-of-the-art instrumentation is an important focus for Advion. We are committed to remaining leaders of scientific excellence in bioanalysis and the purchase of these mass spectrometers exemplifies this focus.”

The API 5000 and API 4000 systems provide the company with the sensitivity and selectivity in analysis necessary to obtain precise and reliable testing results. The API 5000 System is ideal for the detection of low-level molecules. It couples liquid chromatography with Applied Biosystems/MDS Analytical Technologies’ QJet™ ion source technology and triple quadrupole tandem mass spectrometry (LC/MS/MS), a widely used laboratory technique for measuring pharmaceutical compounds and metabolites.

Tom Kurz, President of Commercial Operations, comments, “The increased capacity and flexibility afforded by this investment will allow us to better serve our clients’ need for timely bioanalytical services of the highest quality.”

About Advion BioServices, Inc.
Advion is a scientific leader in bioanalytical and immunoassay services. Advion offers a range of services including LC/MS/MS services, immunoassay services, dose formulation analysis, sample management and storage services. The company is the laboratory of choice for pharmaceutical and biotechnology companies demanding scientific excellence.

More information about the company can be found on its website www.advion.com.

API 4000, API 5000 and QJet are trademarks of Applied Biosystems/MDS Analytical Technologies, a joint venture between Applera Corporation and MDS Inc.

For Advion:
Heather Scollins
Senior Marketing Communication Specialist
Advion BioSciences, Inc.
P: 1.607.266.0665 ext. 333
hscollins@advion.com

April 1, 2008, Ithaca , NY – Advion BioSystems, a leading supplier of microfluidic devices for the life sciences industry, launches the latest advancements in proteomic research – the Advion RePlay and FloTek systems.

RePlay is a new nanoLC tool that provides proteomic researchers with two complementary MS analyses from one injection. Suited for rapid identification of proteins and structural identification of post translational modifications, RePlay splits a chromatographic run into two separations directing one to the MS for analysis while simultaneously directing the other into the Capture Cartridge. Once the initial MS analysis completes, RePlay switches flow and the captured chromatographic separation is then analyzed while the nanoLC system reequilibrates thereby increasing mass spectrometer utilization time while decreasing the need for extra time and sample.

Compatible with all nanosprayers, including MS vendor supplied sprayers, third party sprayers, pulled capillaries, and the ESI Chip, RePlay is also compatible with existing nanoLC systems and mass spectrometers.

Proteomics researchers have demonstrated that a second analysis of the same sample can improve protein and peptide coverage, increase identification of post translational modifications, and improve analytical confidence. Such repeat analysis provides more information by allowing varied analytic conditions and increased analysis time. However, the time for a single nanoLC analysis is generally 60 minutes, and many researchers do not have adequate amounts of sample or time to invest in a reanalysis. RePlay allows the researcher to obtain two analyses without a second injection saving time and sample.

Matthias Mann, a scientific collaborator from the Max Planck Institute, states “The RePlay device was co-developed in our laboratory, and we believe it will have a significant impact on proteomic research.” Jennifer Busby, another RePlay user at Scripps Research, adds, “In a proteomics service laboratory, time is money. RePlay allows me to do more in the same amount of time and thus, increase my mass spectrometer usage.”

Thomas Kurz, President of Commerical Operations, comments on the product launch, “Advion is positioning itself as a leader in microfluidic chemistry. There is a large need in the low flow proteomics market for a device that can improve information content of complex samples, increase expensive mass spectrometer utilization time, and maximize available sample. We have developed RePlay as an add-on product to existing nanoLC/MS systems to address all of these needs, and are pleased with the data we have seen from our users.”

In addition to the RePlay device, Advion is releasing FloTek, a digital nanoflow meter. FloTek allows nanoLC users to quickly and accurately determine flow rates from their existing nanoLC system, a crucial measurement necessary for analysis. The FloTek device is intended to monitor nanoLC performance as well as assist in diagnosing nanoLC system issues. It can be used in conjunction with RePlay or as a stand alone device.

Advion has received patent pending status of RePlay, and is the sole supplier of this technology. Orders for the RePlay and Flotek devices should be placed with a local Advion account manager.

About Advion BioSystems, Inc.
Advion is the scientific leader in microfluidics systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the microfluidics supplier of choice for customers demanding scientific excellence that provides better synthesis, accurate mass analysis, higher yields and greater throughput. More information about the company can be found on their website at www.advion.com.

For Advion:
Amy Boardman
Manager of Corporate Marketing Communications
Advion BioSciences, Inc.
p: 1.607.266.0665 ext. 314
aboardman@advion.com

ITHACA, NY, March 18, 2008 — Advion BioSystems, Inc. announced today that it has signed a non-exclusive joint marketing agreement with Bruker Daltonik, GmbH, a wholly owned subsidiary of Bruker Daltonics Inc. to co-promote its TriVersa NanoMate system with Bruker Daltonics mass spectrometers. Advion is a leading innovator of microfluidic systems for the mass spectrometry (MS) and Positron Emission Tomography (PET) industry, while Bruker Daltonics is a leading manufacturer of mass spectrometry instruments and accessories for pharmaceutical, biochemical and chemical research. The TriVersa NanoMate is an automated nanoelectrospray source that connects to the front of a mass spectrometer. It combines the benefits of liquid chromatography (LC), fraction collection and chip-based infusion in one system. Advion encouraged this agreement to provide greater flexibility to its customers who often have multiple MS systems in their laboratory.

Under the agreement, Advion and Bruker Daltonik GmbH will co-market the TriVersa NanoMate and Bruker MS systems with each company responsible for their individual products. There has been an exchange of instruments to be utilized for applications development and product demonstrations. Placement in the companies’ demonstration laboratories and applications development for joint product promotion gives the TriVersa NanoMate greater exposure to new MS owners and existing Bruker Daltonics customers. Each company will co-promote their products at industry tradeshows and conferences.

“Advion wants to be the recognized leader in microfluidic systems for mass spectrometry and this agreement is another step in that direction,” said Jack Henion, Advion’s Chief Scientific Officer. “Additionally, Bruker’s market position in the life sciences allows Advion’s customers more flexibility to use its equipment as well as opening greater market potential for future sales in proteomic, biomarker, and metabolism applications.”

Alexander Harder, Product Manager, Bruker Daltonik GmbH, added, “We have had many inquiries from current and new customers regarding our compatibility with the Advion technology. This agreement provides our customers with the ability to use the TriVersa NanoMate system with Bruker’s MS range.”

About Bruker Corporation
As of February 26, 2008, the renamed Bruker Corporation has become the parent company of the entire Bruker group of companies. After the closing of the acquisition of the Bruker BioSpin Group, Bruker Corporation now operates in two segments, the life science and analytical (LSA) systems segment, and the international advanced superconductor (IAS) segment. For more information, please visit www.bruker.com.

About Advion BioSystems, Inc.
Advion is the scientific leader in micro-fluidics systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the micro-fluidics supplier of choice for customers demanding scientific excellence that provides better synthesis, accurate mass analysis, higher yields and greater throughput. More information about the company can be found on their website at www.advion.com.

For Advion:
Amy Boardman
Manager of Corporate Marketing Communications
Advion BioSciences, Inc.
p: 1.607.266.0665 ext. 314
aboardman@advion.com

Ithaca, NY, March 12, 2008 – Advion BioSciences, Inc., through its BioSystems subsidiary, announces it has acquired certain assets of its long-standing out-sourced production supplier, Washburn Manufacturing Technologies Inc., located near the company’s headquarters in Ithaca, NY . Under the terms of agreement, Advion BioSystems will absorb nearly the entire manufacturing operation and employees of Washburn Manufacturing into its business effective immediately, including the founder of the production company, Tom Washburn.

The transaction immediately increases Advion’s gross margins and brings vital skill sets to the Company including quick turn development prototyping, machining, injection molding capabilities, and enhanced assembly, test & quality functions. In addition, by bringing the manufacturing in-house allows the Company to better streamline its processes across current and future product lines. This results in increased flexibility and responsiveness to market demands.

Thomas Washburn commented on the acquisition, “I’ve worked with Advion for many years, and this acquisition is a natural fit. This will enhance the products we deliver.” Commenting on the transaction, Advion’s CEO David B. Patteson stated, “Advion is devoted to providing the highest quality products to its customers, and this acquisition places us in a better position to accomplish this goal. Advion’s growth profile has been notable over the past several years. We needed a more fully developed operations base to flex upward with our current systems platforms and those which are planned for launch over the next 18 months.”

Continuing, Timothy McGrath, Advion’s Senior Vice President of Operations stated, “In-sourcing our production is a key element in our ability to continue to provide world class delivery in support of significant future growth initiatives. We are fortunate to have the local skill sets which allow for this transition. It is envisioned that over the next 12 months all of Advion’s product platforms will be produced by the company’s employees in New York , including the NanoTek clinical diagnostic products, currently produced in Knoxville , TN. ”

About Advion BioSystems, Inc.
Advion is the scientific leader in micro-fluidics systems. The company’s scientific knowledge base creates unique nanotechnologies delivering speed, flexibility, and exceptional data quality. Advion is the micro-fluidics supplier of choice for customers demanding scientific excellence that provides better synthesis, accurate mass analysis, higher yields and greater throughput. More information about the company can be found on their website at www.advion.com.

For Advion:
Timothy McGrath
Senior Vice President of Operations
Advion BioSciences, Inc.
P: 607.266.0665 ext. 318
TMcGrath@advion.com